Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Phase 2 N=22 Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Squamous Cell Carcinoma of the Hypopharynx
Primary: Objective Tumor Response Rate (Complete Response [CR] and Partial Response [PR]) Using RECIST Criteria — 6.7; 0 percentage of participants
Phase 2 N=15 Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Neck
Primary: Toxicity — 0; 1; 2 participants
Phase 2 N=95 Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Oropharynx · Squamous Cell Carcinoma of the Larynx · Squamous Cell Carcinoma of the Oral Cavity
Primary: Phase I: Maximum Tolerated Dose — 500 mg/m^2
Phase 2 N=40 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Patient Response — 11; 15; 6; 0 participants
Phase 2 N=33 Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer
Head and Neck Cancer · Cancer of the Pharynx · Cancer of the Larynx
Primary: Llocoregional Recurrence — 27 Participants
Phase 2 N=14 Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Median Overall Survival — 231 Days
Phase 2 N=69 Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Head and Neck Neoplasms
Primary: Percentage of Participants With Objective Response (OR) of Complete Response (CR) or Partial Response (PR) — 12.5 Percentage of participants
Phase 2 N=69 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression-Free Survival (PFS) — 5.1 months
Phase 3 N=658 Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Recurrent and/or Metastatic Head and Neck Cancer
Primary: Overall Survival — 11.1; 9.0 months — p=0.1403
Phase 2 N=62 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Phase 2 N=66 A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
Head and Neck Neoplasms
Primary: Progression Free Survival (PFS) — 4.4 months
Phase 2 N=48 Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Recurrent Head and Neck Cancer · Carcinoma, Squamous Cell of Head and Neck
Primary: Progression Free Survival — 7.9 months
Phase 2 N=40 S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Response Probability (Confirmed Complete and Partial Responses) — 0; 2; 38 participants
Phase 2 N=40 A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Response Rate at 4 Months — 16 percentage of participants
Phase 2 N=52 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Cancer · Carcinoma · Head and Neck Cancer
Primary: Objective Response Rate — 3.9 percentage of participants
N/A N=7 Surgery With or Without Adjuvant Stereotactic Body Radiotherapy
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Phase 2 N=18 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
Head and Neck Cancer
Primary: Response Rate — 4 participants
Phase 2 N=14 Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Progression-Free Survival (PFS). — 370 Days
Phase 2 N=113 PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response
Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck
Primary: Progression Free Survival (PFS) During the First-line Treatment Phase — 6.9; 5.5 Months — p=0.051
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=54 Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Squamous Cell Head and Neck Carcinoma · Recurrent or Metastatic Disease
Primary: Objective Tumor Response Rate — 44 percentage of participants
Phase 2 N=67 S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Overall Survival — 8 months
Phase 2 N=47 Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer
Head and Neck Cancer
Primary: Number of Participants With Complete Response — 39 participants
Phase 2 N=50 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Head and Neck Squamous Cell Carcinoma · Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma · Recurrent Nasopharynx Carcinoma
Primary: Incidence of Toxicity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 — 1; 1; 0; 1 Participants
Phase 2 N=60 Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04
Phase 3 N=320 Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
Head and Neck Cancer
Primary: Progression-free Survival (PFS) Rate — 50; 43; 110; 117 Participants — p=0.83
Phase 2 N=26 A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)
Head and Neck Cancer
Primary: Overall Objective Response — 4; 18; 2; 1 participants
Phase 2 N=48 Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of the Head and Neck
Primary: 1-year Local Progression-free Survival (PFS) — 60 percentage of participants